

Table 1S Simulated values of mid-dose concentrations obtained after suggested dose optimisation and proportions of patients <1mg/L, 1mg/L>&<4mg/L and >4mg/L

Weight Band [kg]	Metabolic group	FM	IM		SM		USM
	SNP Vector	516GG 983TT	516GG 983TC	516GT 983TT	516GT 983TC	516TT 983TT	516GG 983CC
10-13.9	Dose [mg]	300	200		100		50
	C12h [mg/L]	2.02 (0.47-8.04)	2.49 (0.64-9.11)	1.93 (0.50-7.42)	3.71 (1.08-14.01)	2.63 (0.67-10.04)	3.57 (0.83-12.43)
	>4 [mg/L]	21%	29%	20%	46%	30%	45%
	1> & <4 [mg/L]	60%	58%	59%	50%	57%	49%
	<1 [mg/L]	20%	13%	21%	4%	12%	7%
14-19.9	Dose [mg]	400	300		150		50
	C12h [mg/L]	2.11 (0.52-7.86)	2.98 (0.79-10.90)	2.22 (0.57-8.68)	4.30 (1.10-15.77)	3.04 (0.79-11.12)	2.70 (0.79-9.99)
	>4 [mg/L]	22%	36%	24%	53%	37%	30%
	1> & <4 [mg/L]	60%	55%	59%	43%	54%	60%
	<1 [mg/L]	19%	9%	16%	4%	9%	10%
20-24.9	Dose [mg]	600	400		200		100
	C12h [mg/L]	2.55 (0.63-9.98)	3.11 (0.76-12.07)	2.47 (0.62-8.98)	4.6 (1.27-16.79)	3.31 (0.87-12.68)	3.84 (1.13-14.30)
	>4 [mg/L]	29%	38%	28%	57%	41%	47%
	1> & <4 [mg/L]	58%	54%	58%	40%	52%	48%
	<1 [mg/L]	13%	8%	14%	3%	7%	4%
25-29.9	Dose [mg]	600	400		200		100

	C12h [mg/L]	2.10 (0.52-8.12)	2.80 (0.67-10.20)	2.14 (0.54-8.14)	3.92 (1.04-14.74)	2.84 (0.73-10.42)	3.31 (0.93-12.77)
	>4 [mg/L]	22%	34%	22%	49%	34%	42%
	1> & <4 [mg/L]	58%	55%	60%	47%	56%	53%
	<1 [mg/L]	19%	12%	18%	5%	10%	6%
30-39.9	Dose [mg]	600	400		200		100
	C12h [mg/L]	1.80 (0.43-7.11)	2.27 (0.57-8.42)	1.76 (0.45-6.75)	3.30 (0.87-12.59)	2.32 (0.61-8.87)	3.06 (0.77-12.74)
	>4 [mg/L]	16%	24%	16%	40%	26%	36%
	1> & <4 [mg/L]	60%	60%	60%	53%	59%	55%
	<1 [mg/L]	24%	16%	25%	7%	15%	9%

Data presented as median (5th-95th percentile) or percentage. EM (extensive metabolisers) - 516GG|983TT; IM (intermediate metabolisers) - 516GG|983TC or 516GT|983TT, SM (slow metabolisers) - 516TT|983TT or 516GT|983TC; USM (ultra-slow metabolisers) - 516GG|983CC.